The immunosuppressants market has seen considerable growth due to a variety of factors.
• The market size for immunosuppressants has seen a swift expansion in recent times. The market is projected to escalate from $25.94 billion in 2024 to $29.72 billion in 2025, indicating a compound annual growth rate (CAGR) of 14.6%.
The notable growth in the past has been propelled by advancements in transplant medicine, innovation and development of drugs, sanctioning by regulatory authorities, an increase in transplant operations, and proven clinical effectiveness and safety.
The immunosuppressants market is expected to maintain its strong growth trajectory in upcoming years.
• Forecasted to surge rapidly in the coming years, the immunosuppressants market size is projected to reach $48.88 billion by 2029, expanding at a compound annual growth rate (CAGR) of 13.2%.
The upward trajectory in the forecast period could be credited to factors such as targeted therapies and the rise of precision medicine, advances in biologics and biosimilars, the use of immunotherapy combinations, the application of gene therapy and immunomodulation, as well as innovations in drug delivery methods. During the forecasted time frame, there will also be key developments including broader applications, regulatory and safety considerations, the implementation of precision medicine strategies, an increase in telehealth and remote monitoring, along with the incorporation of biosimilars and generics.
The major component fueling the expansion of the immunosuppressant market is the escalating number of organ transplant surgeries like kidney and liver transplants due to the increasing rates of organ failure. For example, the American Kidney Fund, a health organization based in the US, predicts that over 106,000 individuals will be on the national transplant waiting list by June 2022, with 92,000 (or 87%) of them awaiting a kidney transplant in the US. Thus, the rising cases of organ transplants and incidences of organ failure are anticipated to propel the growth of the immunosuppressants market.
The immunosuppressants market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Other Drug Classes
2) By Indication: Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
2) By Monoclonal Antibodies (mAbs): Anti-TNF Agents, Anti-CD20 Agents, Anti-IL-6 Agents
3) By Calcineurin Inhibitors: Cyclosporine, Tacrolimus
4) By mTOR Inhibitors: Sirolimus, Everolimus
5) By Anti-Proliferative Agents: Azathioprine, Mycophenolate Mofetil
6) By Other Drug Classes: Co-Stimulation Blockers, JAK Inhibitors
Phenotypic Personalized Medicine (PPM), a blend of artificial intelligence and doctor intervention, brings a fresh approach to addressing the challenges associated with immunosuppressants. Take tacrolimus as an example - it is the most commonly utilized immunosuppressant in organ transplant patients. However, while the patient is hospitalised, the levels of this immunosuppressant need to be constantly monitored and altered. A computational platform-based PPM approach is employed to mitigate this issue. This approach takes into account the patient's past reactions to the drug dosage, any other medications being taken, as well as current liver and kidney data. With the help of PPM, the doctor has the ability to pinpoint the best drug and dosage combination from a multitude of options. Hence, it is considered that artificial intelligence is paving the path for not just more individualized and efficient drug dosage but also augmenting the decision-making abilities of physicians by giving them clinical data instead of anticipated responses.
Major companies operating in the immunosuppressants market include:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F Hoffmann La Roche Ltd.
• AbbVie Inc.
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Co.
• Mylan Laboratories Inc.
• Teva Pharmaceuticals USA Inc.
• Astellas Pharma Inc.
• Sandoz Inc.
• Aurobindo Pharma Limited
• Hikma Pharmaceuticals plc
• Intas Pharmaceuticals Ltd.
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Ltd.
• Fresenius Kabi USA
• Lupin Pharmaceuticals Inc.
• Strides Pharma Inc.
• Accord Healthcare Ltd.
• RPG Life Sciences Limited
• Genzyme Transgenics Corp.
• Apotex Inc.
North America was the largest region in the immunosuppressants market in 2024. The regions covered in the immunosuppressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.